Related Experiment Video
Updated: May 24, 2025
Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
Targeting TUBG1 in RB1-negative tumors
Lisa Lindström1, Jingkai Zhou1, Bruno O Villoutreix2
1Molecular Pathology, Department of Translational Medicine, Lund University, Malmö, Sweden.
Abstract:
The disruption of microtubule dynamics serves as a pivotal strategy for eliminating tumor cells, despite its accompanying toxicities affecting non-tumor cells. This study investigates the potential of selectively targeting γ-tubulin1 (TUBG1) as a therapeutic strategy in cancer treatment. By elucidating the TUBG1-E2F1-retinoblastoma protein (RB1) network, we introduce a novel compound, 4-(6-((3-Methoxyphenyl)amino)pyrimidin-4-yl)-N,N-dimethylbenzenamine, (L12). L12 treatment enhanced RB1 expression and selectively targeted cells with impaired RB1 signaling, while reduced E2F1 expression attenuated its cytotoxicity. Furthermore, L12-mediated cytotoxicity depends on an E2F1-mediated upregulation of procaspase 3 expression, highlighting the role of E2F1 in the apoptotic response. Unlike traditional tubulin-targeting agents, L12's specificity for tumor cells lies in its inhibitory effects on TUBG1, without affecting the second human isoform of TUBGs, TUBG2. Despite its interaction with specific kinases, the concentrations required for antitumor effects are 100-fold lower than those influencing kinase activities. Subsequent investigations underscore L12's reduced neuronal axonal toxicity compared to vincristine. Lastly, L12 demonstrates promising results in inhibiting tumor growth in xenografted small cell lung cancer models, demonstrating potential specificity toward tumor cells while minimizing adverse effects on healthy tissues. This research emphasizes the potential of TUBG1 inhibitors as a promising advancement in personalized chemotherapy approaches and their potential as a groundbreaking treatment for various cancers.
Insights
A novel compound, L12, selectively targets tumor cells by inhibiting gamma-tubulin1 (TUBG1), a key player in microtubule dynamics. This approach shows promise for personalized cancer chemotherapy with reduced side effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Microtubule disruption is a cancer treatment strategy but causes toxicity.
- Selective targeting of gamma-tubulin1 (TUBG1) offers a potential therapeutic avenue.
- Understanding the TUBG1-E2F1-retinoblastoma protein (RB1) network is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the therapeutic potential of selectively targeting TUBG1 in cancer treatment.
- To elucidate the mechanism of action of a novel compound, L12, targeting the TUBG1-E2F1-RB1 network.
- To evaluate the efficacy and safety profile of L12 in preclinical cancer models.
Main Methods:
- Development and characterization of a novel compound, L12 (4-(6-((3-Methoxyphenyl)amino)pyrimidin-4-yl)-N,N-dimethylbenzenamine).
- In vitro studies to assess L12's effects on TUBG1, E2F1, RB1, and procaspase 3 expression.
- Evaluation of L12's cytotoxicity and apoptotic response in cancer cells.
- In vivo studies using xenografted small cell lung cancer models to assess tumor growth inhibition and toxicity.
Main Results:
- L12 enhanced RB1 expression and selectively targeted cells with impaired RB1 signaling.
- L12-mediated cytotoxicity was dependent on E2F1-upregulated procaspase 3 expression.
- L12 specifically inhibited TUBG1 without affecting TUBG2, unlike traditional tubulin agents.
- L12 demonstrated reduced neuronal axonal toxicity compared to vincristine and inhibited tumor growth in vivo.
Conclusions:
- L12 represents a promising TUBG1 inhibitor with potential for selective cancer chemotherapy.
- The compound's mechanism involves the TUBG1-E2F1-RB1 network and E2F1-mediated apoptosis.
- L12 shows potential for personalized chemotherapy with a favorable safety profile, minimizing adverse effects on healthy tissues.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation
01:23Negative Regulator Molecules